Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,725 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme.
Cueva JF, Palacio I, Churruca C, Herrero A, Pardo B, Constenla M, Santaballa A, Manso L, Estévez P, Maximiano C, Legerén M, Marquina G, de Juan A, Quindós M, Sánchez L, Barquin A, Fernández I, Martín C, Juárez A, Martín T, García Y, Yubero A, Gallego A, Martínez Bueno A, Guerra E, González-Martín A. Cueva JF, et al. Among authors: fernandez i. Eur J Cancer. 2023 Mar;182:3-14. doi: 10.1016/j.ejca.2022.12.023. Epub 2022 Dec 29. Eur J Cancer. 2023. PMID: 36706655
Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER).
Albanell J, Martínez MT, Ramos M, O'Connor M, de la Cruz-Merino L, Santaballa A, Martínez-Jañez N, Moreno F, Fernández I, Alarcón J, Virizuela JA, de la Haba-Rodríguez J, Sánchez-Rovira P, González-Cortijo L, Margelí M, Sánchez-Muñoz A, Antón A, Casas M, Bezares S, Rojo F. Albanell J, et al. Among authors: fernandez i. Eur J Cancer. 2022 Jan;161:26-37. doi: 10.1016/j.ejca.2021.11.010. Epub 2021 Dec 11. Eur J Cancer. 2022. PMID: 34902765 Free article. Clinical Trial.
Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention.
Cueva JF, Antolín S, Calvo L, Fernández I, Ramos M, de Paz L, Mata JG, López R, Constenla M, Pérez E, González A, Pellón ML, Varela S, López T. Cueva JF, et al. Among authors: fernandez i. Clin Transl Oncol. 2017 Sep;19(9):1067-1078. doi: 10.1007/s12094-017-1648-8. Epub 2017 Mar 24. Clin Transl Oncol. 2017. PMID: 28342058 Free PMC article.
Anti-HER2 Therapy Beyond Second-Line for HER2-Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel.
Martínez-Jañez N, Chacón I, de Juan A, Cruz-Merino L, Del Barco S, Fernández I, García-Teijido P, Gómez-Bernal A, Plazaola A, Ponce J, Servitja S, Zamora P. Martínez-Jañez N, et al. Among authors: fernandez i. Breast Care (Basel). 2016 Apr;11(2):133-8. doi: 10.1159/000443601. Epub 2016 Feb 8. Breast Care (Basel). 2016. PMID: 27239176 Free PMC article.
Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial.
Tibau A, Martínez MT, Ramos M, De La Cruz-Merino L, Santaballa A, O'Connor M, Martínez-Jañez N, Moreno F, Fernández I, Virizuela JA, Alarcón J, de La Haba-Rodríguez J, Sánchez-Rovira P, Albacar CR, Bueno Muiño C, Kelly C, Casas M, Bezares S, Rosell L, Albanell J. Tibau A, et al. Among authors: fernandez i. Ther Adv Med Oncol. 2023 Jan 19;15:17588359221148921. doi: 10.1177/17588359221148921. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36743520 Free PMC article.
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.
Balana C, De Las Penas R, Sepúlveda JM, Gil-Gil MJ, Luque R, Gallego O, Carrato C, Sanz C, Reynes G, Herrero A, Ramirez JL, Pérez-Segura P, Berrocal A, Vieitez JM, Garcia A, Vazquez-Estevez S, Peralta S, Fernandez I, Henriquez I, Martinez-Garcia M, De la Cruz JJ, Capellades J, Giner P, Villà S. Balana C, et al. Among authors: fernandez i. J Neurooncol. 2016 May;127(3):569-79. doi: 10.1007/s11060-016-2065-5. Epub 2016 Feb 3. J Neurooncol. 2016. PMID: 26847813 Clinical Trial.
A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma.
Rubio JC, Vázquez S, Vázquez F, Amenedo M, Fírvida JL, Mel JR, Huidobro G, Alvarez E, Lázaro M, Alonso G, Fernández I; Galician Group of Lung Cancer (GGCP in the Spanish acronym). Rubio JC, et al. Among authors: fernandez i. Cancer Chemother Pharmacol. 2009 Jul;64(2):379-84. doi: 10.1007/s00280-008-0884-6. Epub 2009 Jan 13. Cancer Chemother Pharmacol. 2009. PMID: 19139896 Clinical Trial.
SEOM clinical guideline on unknown primary cancer (2017).
Losa F, Soler G, Casado A, Estival A, Fernández I, Giménez S, Longo F, Pazo-Cid R, Salgado J, Seguí MÁ. Losa F, et al. Among authors: fernandez i. Clin Transl Oncol. 2018 Jan;20(1):89-96. doi: 10.1007/s12094-017-1807-y. Epub 2017 Dec 11. Clin Transl Oncol. 2018. PMID: 29230692 Free PMC article.
SEOM-GECOD clinical guideline for unknown primary cancer (2021).
Losa F, Fernández I, Etxaniz O, Giménez A, Gomila P, Iglesias L, Longo F, Nogales E, Sánchez A, Soler G. Losa F, et al. Among authors: fernandez i. Clin Transl Oncol. 2022 Apr;24(4):681-692. doi: 10.1007/s12094-022-02806-x. Epub 2022 Mar 23. Clin Transl Oncol. 2022. PMID: 35320504 Free PMC article.
1,725 results